Globus Medical Surges 8.47% on $210M Volume as Q2 Sales Hit $745M Propelling It into Top 500 High-Volume Stocks

Globus Medical (GMED) surged 8.47% on Aug. 8, 2025, with a trading volume of $210 million, up 70.35% from the prior day, as the firm reported Q2 results. The company posted $745.3 million in net sales, a 18.4% year-over-year increase, driven by 20.3% growth in U.S. sales and 11.0% international sales. GAAP net income rose to $202.8 million, including a $110.6 million bargain purchase gain, while non-GAAP diluted EPS reached $0.86, a 14.1% beat on estimates.

Management highlighted sustained momentum in the U.S. Spine business, which grew 5.7% year-over-year and 7.4% on a day-adjusted basis. CEO Keith Pfeil emphasized progress in robotic-assisted surgery integration and product pipeline expansion. CFO Kyle Kline noted record non-GAAP earnings and successful synergy actions from the recent Nevro acquisition. The company reaffirmed 2025 revenue guidance of $2.8–$2.9 billion and non-GAAP EPS of $3.00–$3.30, reflecting confidence in operational efficiency and long-term growth.

A backtested strategy of holding the top 500 high-volume stocks for one day returned 166.71% from 2022 to 2025, outperforming the benchmark by 137.53%. This underscores liquidity-driven momentum in volatile markets, though such strategies are not suited for long-term investing.